Max Robotics — Global Service Robot Directory + US Certification

About

David P. Carbone is a leading figure in thoracic oncology, whose work has fundamentally shaped the understanding and treatment of lung cancer. His research spans the molecular staging of disease, pharmacogenomics, and the transformative role of immunotherapy. A major contribution is his elucidation of how circulating tumour DNA (ctDNA) dynamics can predict responses to neoadjuvant immunotherapy, a finding that promises to personalize surgical strategies for non-small cell lung cancer (NSCLC). His landmark reviews, including the highly cited “Cancer of the Lung” (2020), have synthesized decades of progress, guiding clinical practice and research priorities. With over 42 citations on his most recent work alone, Carbone’s impact is evident in the shift toward biomarker-driven, less invasive treatment paradigms. He has also been instrumental in advancing early-stage lung cancer care, highlighting a 40-year arc of progress from palliative to curative-intent therapies. Through his leadership in clinical trials and molecular diagnostics, Carbone continues to bridge the gap between laboratory discovery and patient outcomes, cementing his legacy as a pioneer in the fight against one of the deadliest cancers.